Turakhia Minang 4

What Happened

• Minang Turakhia, iRhythm's Chief Medical/Scientific Officer & EVP, Advanced Technology, was granted 10,034 Restricted Stock Units (RSUs) on February 25, 2026. The Form 4 reports the acquisition at $0.00 (award/grant), meaning this was a compensation grant rather than a market purchase.

Key Details

• Transaction date and type: 2026-02-25 — Award/Grant of 10,034 RSUs (code A).
• Reported price/value: $0.00 reported on the Form 4 (award grant).
• Vesting: 25% of the RSUs vest on March 1, 2027, then 25% on each one-year anniversary thereafter, contingent on continued service (per footnote).
• What an RSU is: each RSU represents a contingent right to receive one share of common stock upon vesting.
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Form filed 2026-02-27 (appears timely under standard Form 4 rules).

Context

• This is a standard equity compensation grant to an executive (retention/incentive), not an open-market purchase or sale. Such grants are routine and reflect compensation policy rather than direct trading sentiment; they do not indicate an immediate purchase of shares until/if the RSUs vest and are settled.